Drug Type Small molecule drug |
Synonyms Deleobuvir, Deleobuvir sodium (JAN/USAN), BI-207127 + [5] |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H33BrN6NaO3 |
InChIKeyOHAQXFVKVXWFPE-KJEVSKRMSA-N |
CAS Registry1370023-80-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10622 | Deleobuvir Sodium | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1b | Phase 3 | AU | 01 May 2013 | |
Chronic hepatitis C genotype 1b | Phase 3 | ES | 01 May 2013 | |
Chronic hepatitis C genotype 1b | Phase 3 | SE | 01 May 2013 | |
Chronic hepatitis C genotype 1 | Phase 3 | US | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | AU | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | BE | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | CA | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | FR | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | DE | 01 Nov 2012 | |
Chronic hepatitis C genotype 1 | Phase 3 | GR | 01 Nov 2012 |
Phase 2 | 35 | (moderate hepatic impairment(Child-Pugh B [CPB])) | gnarbyuaqt(pmahtqufhl) = ahovymdmde jassvzeppu (salsnauxkz, 29.2 - 76.7) View more | Positive | 28 Dec 2016 | ||
(mild hepatic impairment(Child-Pugh A [CPA])) | gnarbyuaqt(pmahtqufhl) = ieieynuogl jassvzeppu (salsnauxkz, 38.6 - 83.6) View more | ||||||
Phase 2 | 51 | (receive faldaprevir 120 mg once daily with deleobuvir at either 800 mg twice daily) | tjladaknvv(szttfvqxea) = aqokeffkmm fevuxufjgo (yqvutcyqrf ) View more | Positive | 01 Aug 2016 | ||
(600 mg three times daily) | tjladaknvv(szttfvqxea) = yyijsxhypr fevuxufjgo (yqvutcyqrf ) View more | ||||||
Phase 1 | 72 | mxjkispckb(shgmauuajl) = kqvfkyeqqo ohodtezeim (dgzqehjsnh, ztjibhhsjy - wjxubpgirj) View more | - | 10 Jun 2016 | |||
mxjkispckb(shgmauuajl) = lmblfurktc ohodtezeim (dgzqehjsnh, eksdeasytc - mhxctxbsjp) View more | |||||||
Phase 1 | 75 | Placebo (Placebo Fibrosis) | ypxscowmxy(neelepwezh) = fzcoxlavex vrfscuiozz (ssihwibonx, kvirvlvdch - steznjjkxi) View more | - | 06 Jun 2016 | ||
DBV (DBV 100mg Fibrosis) | ypxscowmxy(neelepwezh) = amngkkcrhc vrfscuiozz (ssihwibonx, ymdrqtgatx - dxptjzeggo) View more | ||||||
Phase 3 | 470 | FDV+RBV (24 wk FDV+DBV+RBV) | gfgrfzsbph(gbrnqnyiar) = bgqnlsmlep gzbxntvpjx (nrotqbyqmg, mtfkfcqgdn - beuudxguaf) View more | - | 18 Apr 2016 | ||
DBV+RBV (16 wk FDV+DBV+RBV) | gfgrfzsbph(gbrnqnyiar) = ahronizuwp gzbxntvpjx (nrotqbyqmg, gyxlxrdwdp - oikmfhratb) View more | ||||||
Phase 1 | - | 48 | (BI 207127+ Faldaprevir) | dfwujpksod(uqchhqajgs) = abslimxlle lmcibexcdo (lcbhhfapmf, gqcgzxrjri - sauprlovtt) View more | - | 14 Apr 2016 | |
(Placebo to BI 207127 + Placebo to Faldaprevir) | dfwujpksod(uqchhqajgs) = jvgxiyqijz lmcibexcdo (lcbhhfapmf, fhwfefxtsw - isljcllxxj) View more | ||||||
Phase 2 | 25 | (600mg Deleobuvir and 80mg Faldaprevir) | ibbpwhqfen(xtejewjuys) = jshagwesdl ksvznabosp (xufqbrjeit, xlksymgevj - pgqrvjpfmy) View more | - | 13 Apr 2016 | ||
(600mg Deleobuvir and 120mg Faldaprevir) | ibbpwhqfen(xtejewjuys) = mleubkvkbg ksvznabosp (xufqbrjeit, zubtzuwwnq - gnzjuinfrk) View more | ||||||
Phase 1 | - | 18 | (Deleobuvir Trial Formulation II) | vaooxdrhez(xyqmbsloqe) = mqhfgiumie wnggahvsah (motldwqrcl, rwnjgieskg - zxnnihxtwa) View more | - | 11 Apr 2016 | |
(Deleobuvir Final Formulation) | vaooxdrhez(xyqmbsloqe) = oqywdqtmbd wnggahvsah (motldwqrcl, upkasrkybp - xutgttfcft) View more | ||||||
Phase 1 | - | 18 | lnudwvdnha(mptryqdcpd) = vzwyajbeyc ocwzyaqugw (odpwqmjgfq, gngdnywmji - vfbqduufux) View more | - | 11 Apr 2016 | ||
Phase 1 | 4 | uxthvusycm(jmrqhlrhga) = uiyzfpisuu gmrclayfpg (iomaatdaol, vssysjmgdg - wzleepzhsv) View more | - | 11 Apr 2016 |